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Myricetin improves endurance 
capacity and mitochondrial density 
by activating SIRT1 and PGC-1α
Hoe-Yune Jung  1,5,6, Dongyeop Lee2, Hye Guk Ryu  2, Bo-Hwa Choi6, Younghoon Go8,10, 
Namgyu Lee2,11, Dohyun Lee2, Heehwa G. Son2, Jongsu Jeon1,5, Seong-Hoon Kim2, Jong Hyuk 
Yoon2, Seon-Min Park6,7, Seung-Jae V. Lee  1,2,3,4, In-Kyu Lee8, Kwan Yong Choi1,2, Sung Ho 
Ryu1,2, Kazunari Nohara9, Seung-Hee Yoo9, Zheng Chen9 & Kyong-Tai Kim1,2
Robust mitochondrial respiration provides energy to support physical performance and physiological 
well-being, whereas mitochondrial malfunction is associated with various pathologies and reduced 
longevity. In the current study, we tested whether myricetin, a natural flavonol with diverse biological 
activities, may impact mitochondrial function and longevity. The mice were orally administered 
myricetin (50 mg/kg/day) for 3 weeks. Myricetin significantly potentiated aerobic capacity in mice, 
as evidenced by their increased running time and distance. The elevated mitochondrial function was 
associated with induction of genes for oxidative phosphorylation and mitochondrial biogenesis in 
metabolically active tissues. Importantly, myricetin treatment led to decreased PGC-1α acetylation 
through SIRT1 activation. Furthermore, myricetin significantly improved the healthspan and lifespan 
of wild-type, but not Sir-2.1-deficient, C. elegans. These results demonstrate that myricetin enhances 
mitochondrial activity, possibly by activating PGC-1α and SIRT1, to improve physical endurance, 
strongly suggesting myricetin as a mitochondria-activating agent.
Mitochondria are the primary site for cellular energy production, providing ATPs through aerobic respiration. 
Conversely, impaired mitochondrial function has been implicated in various diseases, particularly affecting met-
abolic, cardiovascular and nervous systems1, 2. For example, it has been well documented that metabolic and car-
diovascular risk factors are correlated with low aerobic capacity and reduced muscle expression of genes required 
for oxidative phosphorylation (OXPHOS) and mitochondrial biogenesis3. One such gene encodes the peroxisome 
proliferator-activated receptor γ coactivator, PGC-1α4. PGC-1α functions as a coactivator for nuclear receptors 
and plays a predominant regulatory role in energy metabolism and mitochondrial biogenesis and respiration5, 6. 
Previous studies have revealed that PGC-1α controls muscle fiber-type switching7 and adaptive thermogenesis 
in the brown adipose tissue (BAT)8. Another group of key regulators capable of promoting mitochondriogene-
sis and enhancing respiration are the sirtuin family of deacetylases (SIRTs)9. In mammals, seven sirtuin genes 
have been identified (Sirt1–Sirt7)10. Among them, SIRT1 belongs to class III histone/protein deacetylases, and its 
1Department of Integrative Biosciences & Biotechnology, Pohang University of Science and Technology(POSTECH), 
77 Cheongam-Ro, Pohang, Gyeongbuk, 37673, Republic of Korea. 2Department of Life Sciences, Pohang University 
of Science and Technology(POSTECH), 77 Cheongam-Ro, Pohang, Gyeongbuk, 37673, Republic of Korea. 
3Information Technology Convergence Engineering, Pohang University of Science and Technology(POSTECH), 
77 Cheongam-Ro, Pohang, Gyeongbuk, 37673, Republic of Korea. 4School of Interdisciplinary Bioscience and 
Bioengineering, Pohang University of Science and Technology(POSTECH), 77 Cheongam-Ro, Pohang, Gyeongbuk, 
37673, Republic of Korea. 5R&D Center, NovMetaPharma Co., Ltd., 394 Jigok-Ro, Pohang, Gyeongbuk, 37668, 
Republic of Korea. 6Advanced Bio Convergence Center, Pohang Technopark, 394 Jigok-Ro, Pohang, Gyeongbuk, 
37668, Republic of Korea. 7Department of Veterinary Medicine, Kyungpook, National University, Daegu, 41566, 
Republic of Korea. 8Leading-Edge Research Center for Drug Discovery and Development for Diabetes and Metabolic 
Disease, Kyungpook National University Hospital, Daegu, 41407, South Korea. 9Department of Biochemistry and 
Molecular Biology, The University of Texas Health Science Center at Houston, 6431 Fannin St., Houston, TX 77030, 
USA. 10Korean Medicine (KM) Application Center, Korea Institute of Oriental Medicine (KIOM), 41062, Daegu, 
Republic of Korea. 11Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, 
Worcester, MA, 01605, USA. Correspondence and requests for materials should be addressed to K.-T.K. (email: ktk@
postech.ac.kr)
Received: 28 November 2016
Accepted: 26 May 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 6237  | DOI:10.1038/s41598-017-05303-2
dysregulation has been shown to be involved in aging, metabolic diseases and inflammation11–13. Under caloric 
restriction (CR), SIRT1 functions coordinately with PGC-1α to promote metabolic adaptation14. In particular, 
SIRT1 activates PGC-1α by deacetylation of lysine residues, thereby enhancing mitochondrial biogenesis15. The 
deacetylase activity of SIRT proteins is dependent on the intracellular NAD + content16.
Given the close association between aging and mitochondrial function, it is conceivable that a small-molecular 
activator of SIRT1 can display anti-aging efficacies. On the other hand, an age-related decline in mitochon-
drial function is thought to be a contributing factor to insulin resistance and cancers1. Interestingly, CR, a 
well-established anti-aging manipulation conserved in various organisms, is known to improve mitochondrial 
function17. Therefore, SIRT1-activating agents can impinge upon overlapping pathways that are also modified by 
CR and serve as potential therapeutic regimens for diseases of aging. In that regard, resveratrol, a well-known 
SIRT1 activator, has been shown to confer protection against metabolic disorders by activating mitochondrial 
respiration and biogenesis12.
Myricetin is a widely distributed flavonol compound found in many plants, including tea, berries, fruits, 
vegetables, and medicinal herbs. A growing body of literature provided evidence that myricetin can prevent or 
decelerate the progression of various diseases, including cancer18, metabolic disease19, neurodegenerative dis-
eases20, skin disease21 and inflammatory disorders22, as well as extend the lifespan of Caenorhabditis elegans23, 24. 
Corresponding to its pleiotropic roles in improving health and preventing or treating chronic diseases, myricetin 
has been shown to target diverse cellular pathways under varying conditions25, revealing a mechanistic complex-
ity that warrants further investigation.
In this study we investigated the function and mechanism of myricetin in energy homeostasis in metazoans. 
Studies in mice showed that myricetin potently induced mitochondrial activity, increased muscle strength, and 
improved cold resistance tolerance. These effects correlated with broad gene expression reprograming by myri-
cetin in metabolically active tissues and required SIRT1-dependent PGC-1α deacetylation. Importantly, using 
C. elegans as an aging model, we showed that the anti-aging and motility-enhancing efficacies of myricetin were 
attenuated in SIR-2.1/SIRT1 mutant, yet remained largely intact in DAF-16/FOXO and AAK-2/AMPK mutant 
animals. Therefore, myricetin is a key regulator of mitochondrial function and energy homeostasis, via a mecha-
nistic pathway requiring PGC-1α deacetylation by SIRT1.
Results
Myricetin improved the aerobic capacity in muscle. Previous studies have shown that decreased aer-
obic capacity and mitochondrial oxidative phosphorylation are associated with reduced longevity12. Myricetin is 
known to extend lifespan in C. elegans, yet it is unknown whether it impacts endurance and mitochondrial func-
tion. To address this question, especially in mammals, we first investigated physiological and behavioral effects of 
myricetin in mice. Male ICR mice were administered with myricetin at 50 mg/kg/day for 3 weeks, with a group 
of untreated mice as controls. Treadmill endurance test revealed that mice treated with myricetin displayed twice 
greater run-to-exhaustion distance and time compared with controls (Fig. 1a,b). In contrast, hot-plate pain test 
showed no difference in pain sensitivity between myricetin-treated and nontreated control mice (Figure S1e), 
excluding the possibility that enhanced endurance capacity might be due to altered pain sensitivity. Interestingly, 
relative to nontreated mice, the myricetin-treated mice displayed increased muscle strength (Fig. 1d) and mark-
edly improved motor coordination in the accelerating rotarod test (Fig. 1c). These results, together with the data 
from the treadmill exercise test, suggest that myricetin improves motor function.
These beneficial effects of myricetin on motor function were not due to decreased body weight and food 
intake, as the amount (kcal) of food consumed per mouse over a 24 hr period and body weight were unchanged 
(Figure S1a). Myricetin, at the dose given, did not induce hepatic and other overt toxicity, since the liver and kid-
ney histo-morphology were normal and the serum levels of alanine aminotransferase, aspartate aminotransferase 
and various markers (Table S1) were unchanged (Figure S1d). In addition, coat maintenance, stool composition, 
and water intake (data not shown) were unaffected, indicating that myricetin was well tolerated by the animals.
Myricetin enhanced mitochondrial density in skeletal muscle and BAT. Certain natural polyphe-
nolic compounds, such as resveratrol, have shown endurance enhancing activities by promoting mitochondrial 
density and energy expenditure12. Next, we directly investigated whether the myricetin-mediated increase in 
muscle endurance enhancing activities were a result of metabolic enhancement, specifically elevated mito-
chondrial respiration. We first conducted indirect calorimetry to examine the effect of myricetin on energy 
expenditure (EE) in mice. Basal EE, as measured by oxygen (O2) consumption, was significantly increased in 
myricetin-treated mice (Fig. 1e), but their ambulatory locomotor activity and food intake were not changed 
(Figs S1c and 1f). To assess the effect of myricetin on adaptive thermogenesis, we performed a cold tolerance test. 
Myricetin-treated mice were found to better maintain body temperature compared with control mice, indicat-
ing its beneficial role in adaptive thermogenesis (Fig. 1g). In the mouse, the major site of heat production is the 
brown adipose tissue (BAT). Interestingly, morphometric analysis of BAT mitochondria, by electron microscopy, 
revealed clearly larger mitochondrial structures due to enriched cristae in myricetin-treated mice as compared 
to those in nontreated animals (Fig. 2a,b). In adult human, however, skeletal muscle is the predominant tissue 
providing the majority of mitochondrial capacity for EE. Mitochondria are dynamic organelles that can change in 
number and morphology within a cell and morphological dynamics of mitochondria are linked to regulation of 
many specific cell functions. The mitochondria of healthy cells exhibit elongated and tubular morphology, so we 
identified and quantified mitochondria morphology in each image, and the percent of elongated mitochondria 
was calculated. Myricetin-treated mice had a higher percentage of elongated mitochondria in BAT and liver com-
pared with the nontreated mice (Figure S2). In skeletal muscle, myricetin-associated mitochondrial expansion 
was evidenced by increased mitochondrial size (Fig. 2a,b) and D-loop content (Fig. 2c). Similar changes were 
observed in C2C12 myotubes treated with myricetin (Figure S3a). We also observed increases in citrate synthase 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 6237  | DOI:10.1038/s41598-017-05303-2
Figure 1. Myricetin improved motor function and energy expenditure (EE). (a,b) The effect of myricetin on 
endurance, as measured by a treadmill exercise test. The average run-until-exhaustion distance (a) and time  
(b) are presented for animals treated with PBS or myricetin at 50 mg/kg (n = 10 animals/group). (c,d) Behavior tests 
to evaluate mouse sensorimotor function using a rotarod (c), and grip strength test (d) (n = 10 animals/group). 
(e) EE as measured by changes in O2 consumption in indirect calorimetry over 24 hr. Average VO2 during light 
and dark cycles in mice administered myricetin or not are shown in the graph on the right (n = 6~8 animals/
group). (f) Myricetin treated mice showed no effect on food intake of mice. (g) The internal body temperature 
during a cold tolerance test (4 °C for 6 hr). n = 4 animals/group. Unpaired Student’s t-tests, * = P < 0.05, 
** = P < 0.005, *** = P < 0.0005. Values represent means ± SEM.
www.nature.com/scientificreports/
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Figure 2. Myricetin increased mitochondrial activity in BAT and skeletal muscle. (a) Representative electron 
microscopy images of liver, BAT and skeletal muscle tissues from control and myricetin-treated mice. Scale 
bar: 2 μm. (b) Quantification of mitochondria area of the indicated tissue. Mitochondria area was measured 
in liver (91–117 individual mitochondria), BAT (94–134), and skeletal muscle (117–173). N = 3–4 animals/
group. (c) D-loop regions of mitochondrial DNA (mtDNA) isolated from gastrocnemius muscle, BAT, and liver 
(n = 4 animals/group). (d) Activity of the citrate synthase, as measured with homogenates of BAT, liver, and 
gastrocnemius fibers isolated from myricetin-treated and nontreated mice (n = 3~6 animals/group). Unpaired 
Student’s t-tests, *=P < 0.05, **=P < 0.005, ***=P < 0.0005. Values represent means ± SEM.
www.nature.com/scientificreports/
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activity in muscle and BAT homogenates, further supporting that myricetin enhanced mitochondrial activity 
and consequently improved endurance and adaptive thermogenesis in mice (Fig. 2d). To extend the results on 
BAT and muscle, we next examined the effect on liver, another important mitochondria-rich metabolic organ. 
Measurement of mitochondrial mass by electron microscopy showed that myricetin increased mitochondrial area 
in treated mice relative to controls (Fig. 2a,b), as evidenced by both mitochondrial size increase (Fig. 2a,b) and 
D-loop content (Fig. 2c). However, citrate synthase activity in liver was unaltered by myricetin (Fig. 2d), indicat-
ing tissue-dependent variable effects of myricetin.
Myricetin reprogramed gene expression in metabolically active tissues. To understand the 
molecular basis for the myricetin-mediated mitochondrial enhancement, we performed quantitative RT-PCR 
to examine expressions of genes important for mitochondrial biogenesis and functions in muscle, BAT and liver. 
We first measured the expression of PGC-1α and several other genes of its targets, as well as Sirt112. Sirt1 and 
PGC-1α mRNA expression was significantly induced in these tissues from myricetin-treated mice (Fig. 3a–c). 
The gene encoding nuclear respiratory factor-1 (NRF-1), indispensable for the expression of key mitochondrial 
encoded genes26–28, was also markedly increased by myricetin. Several other PGC-1α targets were also activated29, 
including genes involved in fiber-type markers (MB: myoglobin) as well as PPARβ/δ genes. Of note, it has been 
shown that PPARβ/δ agonists increase oxidative myofibers and running endurance in adult mice30. Similar gene 
induction results were observed in C2C12 myotubes (Figure S3b).
As predicted from the electron microscopy and cold tolerance test results, we noted a significant increase in 
BAT gene expression related to energy homeostasis (Fig. 3a). In particular, PGC-1α, PPARα, and UCP-1 mRNA 
levels were all induced by myricetin. PPARα activates genes important for β-oxidation of fatty acids31, and UCP-1 
is mainly responsible for heat production in BAT via the uncoupling of respiration from ATP synthesis32. In 
liver, myricetin also induced increased expression of PGC-1α, PPARβ/δ, and PPARγ along with Sirt1. However, 
myricetin-induced gene expression showed tissue specificity in those tested, suggesting that myricetin differen-
tially regulates signaling pathways involved in energy homeostasis in distinct metabolic tissues.
Myricetin induced PGC-1α activity through SIRT1. Apart from gene regulation (Fig. 3a–c), PGC-1α 
can also be modulated at the posttranslational level by protein modification with acetylation, which significantly 
impacts its activity14. Therefore, we compared PGC-1α acetylation in skeletal muscle between the treatment 
groups (Fig. 3d). In gastrocnemius muscle, we observed that the ratio of acetylated vs. total nuclear PGC-1α 
protein was significantly decreased in myricetin-treated mice, suggesting that PGC-1α activity was also increased 
(Fig. 3d). We found that deacetylase activity of SIRT was associated with an increase in the NAD+ levels in muscle 
from myricetin administered mice compared to vehicle group (Figure S4a). This is in line with a slight increase 
in NADH levels (Figure S4b) and an increase in the NAD+∶NADH ratio (Figure S4c). To determine whether the 
effect of myricetin on mitochondrial function was mediated by SIRT112, we transfected C2C12 myotubes with a 
specific short interfering RNA (siRNA) directed against Sirt1 or a control siRNA. Sirt1 siRNA was found to effec-
tively reduce endogenous SIRT1 levels (Fig. 3e, left panel). Interestingly the SIRT1 knockdown largely blocked the 
myricetin-induced PGC-1α expression (Fig. 3e, right panels). These results indicate bimodal roles of myricetin in 
PGC-1α induction, namely both gene activation33 and post-translational deacetylation by SIRT1.
Myricetin improved locomotion and delays aging through sir-2.1/Sirt1 in C. elegans. We then 
examined the role of myricetin in organismal aging by using the roundworm C. elegans, an excellent model 
animal for aging research. Consistent with previous reports23, 24, we found that myricetin treatment significantly 
increased the lifespan of wild-type C. elegans (Fig. 4a). In addition, myricetin also markedly enhanced the mobil-
ity of aged worms (Fig. 4b–d), compared with a diminished effect in young worms (Figure S5a–S5c). These results 
suggest that myricetin delays aging in C. elegans. Next, we asked which genetic factors mediate the anti-aging 
effect of myricetin. SIR-2.1/SIRT1, DAF-16/FOXO and AAK-2/AMPK are among key anti-aging longevity fac-
tors that are conserved in many species34. We therefore measured the lifespan of mutant worms that are defective 
in each of these three genes with or without myricetin treatment. Remarkably, myricetin did not increase the 
lifespan of SIRT1 mutant (Fig. 4e), while significantly lengthening that of FOXO or AMPK mutants (Fig. 4f,g). In 
accordance, myricetin failed to enhance the locomotion capacity of aged SIRT1 mutants (Figs 4h and S5d). These 
data suggest that myricetin treatment delays organismal aging in a SIRT1-dependent manner.
Discussion
In summary, our current study reveals a robust effect of the natural flavonol myricetin in mouse energy metabo-
lism. Using physiological and behavioral approaches, we showed that myricetin improved mouse energy expend-
iture and mitochondrial function in metabolically active organs including skeletal muscle and BAT. In contrast, 
no effect on mitochondrial function was observed in liver (Fig. 2d), indicating a certain tissue specificity in 
myricetin’s effects. Molecular analyses revealed a bimodal effect of myricetin on PGC-1α expression induction 
and post-translational deacetylation via SIRT1, both serving to promote mitochondrial function and biogenesis. 
Using C. elegans as an aging model, we showed that the anti-aging effect of myricetin is critically dependent on 
SIRT1, illustrating a mechanistic pathway involving SIRT1 and PGC-1α that mediates the beneficial effects of 
myricetin on mitochondrial function and physiological well-being.
The PGC-1α expression was found to decrease in skeletal muscles from mice lacking the sirtuin family deacetylase 
SIRT33. Conversely, SIRT1 overexpression or activation in differentiated C2C12 myotubes increased PGC-1α mRNA 
expression33. On the other hand, myricetin35, also induces PGC-1α activity by facilitating SIRT1-mediated deacetyl-
ation. Changes in NAD+ are generally translated into altered SIRT1 activity9. The higher NAD+ levels in myricetin 
administered mice were indeed reflected in hypoacetylation of the SIRT1 substrate PGC-1α, indicative of increased 
www.nature.com/scientificreports/
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Figure 3. Myricetin increased gene expression important for mitochondrial function and biogenesis in mice. 
(a–c) Relative mRNA expression levels of key genes related to mitochondrial function as measured by RT-qPCR 
in the BAT (a), gastrocnemius muscle (b), and live (c) from PBS or myricetin-treated mice (n = 3~4 animals/
group). Data represent mRNA levels relative to β-actin and are shown as means ± SEM. (d) Representative 
western blots and quantification showing the relative amount of acetylated versus total PGC-1 protein in 
gastrocnemius muscle. PGC-1α was immunoprecipitated (IP) from nuclear extracts and then immunoblotted 
with either an anti-acetylated lysine antibody to determine the extent of PGC-1α acetylation (Ac-Lys) or an 
anti-PGC-1α antibody to determine the total amount of PGC-1α. N = 4 animals/group. (e) C2C12 myotubes 
were transfected with a Sirt1 siRNA or a control siRNA. Following 24 hr incubation with DMSO or myricetin 
(100 μM), cells were harvested for protein and RNA extraction. A representative western blot showing SIRT1 
protein expression in these cells is shown. Actin was used as a loading control. The mRNA expression levels 
of Sirt1 and PGC-1α were determined by RT-qPCR. Values represent the mRNA levels relative to β-actin, 
Unpaired Student’s t-tests, *=P < 0.05, **=P < 0.005, ***=P < 0.0005. Values represent means ± SEM.
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SIRT1 activity (Figs 3d and 4a). The effects of myricetin on PGC-1α gene expression were dependent on the presence 
of the SIRT1 and were lost when SIRT1 expression was downregulated in C2C12 myotubes by siRNA. These obser-
vations together support dual roles of myricetin and SIRT1 in promoting PGC-1α expression and activity.
Figure 4. Myricetin improved locomotion and delayed aging in C. elegans via SIRT1. (a) Myricetin increased 
the lifespan of wild-type C. elegans. (b) Myricetin treatments increased the body bending rates of old (day 
10 adult) wild-type C. elegans. (c) Enhanced motility of myricetin-treated worms measured by Multi-Worm 
Tracker at day 9 of adulthood. (d) Average speed of the worms measured for 1 min shown in panel B (n ≥ 11). 
(e) SIRT1/sir-2.1(ok434) [SIRT1(−)] mutations suppressed the lifespan-extending effect of myricetin. (f,g) 
Myricetin extended the lifespan of FOXO/daf-16(mu86) [FOXO(−)] mutants (f) and AMPK/aak-2(ok524) 
[AMPK(−)] mutants (g). (h) Myricetin treatments did not increase the body bending rates of old (day 10 adult) 
SIRT1 mutants (n = 15). Error bars represent standard error of the mean (SEM) (two-tailed Student’s t-tests, 
**p < 0.01). See Supplemental Table S2 for additional repeats and statistical analysis.
www.nature.com/scientificreports/
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Impaired mitochondrial function is also associated with rapid onset of symptoms commonly seen in the 
elderly, such as type 2 diabetes, neurodegeneration, and muscle loss36–38 and treatments that enhance mitochon-
drial function can delay the progression of these age-related diseases12, 39, 40. In addition to its locomotion func-
tion, skeletal muscle is also a pivotal tissue responsible for insulin-stimulated glucose uptake and hence energy 
homeostasis, and reduced mitochondrial function in muscle has been shown to play an essential role in the 
development of insulin resistance with obesity41. Together, activation of pathways upstream of mitochondrial 
biogenesis, such as myricetin-dependent PGC-1α activation, may show efficacy in treating or delaying these 
debilitating diseases.
Previous studies examined the role of FOXO in the myricetin-induced longevity in C. elegans, but other lon-
gevity factors were not experimentally tested23, 24. In this study, we investigated several key regulators of aging 
and metabolism such as SIRT1, FOXO, and AMPK42. Consistent with our mouse functional data, the worm 
SIRT1 homolog appeared to mediate the longevity effect of myricetin in C. elegans. SIRT1 is also known to 
mediate the lifespan extension by CR in C. elegans43. As CR is known to promote mitochondrial activity44, the 
mitochondria-enhancing mechanism by which myricetin extends lifespan and healthspan is likely to be con-
served from nematodes to mammals. However, C. elegans does not express a PGC-1α homolog29, suggesting 
a novel factor mediating the lifespan-extending effects of myricetin downstream of SIRT1 in C. elegans. Our 
data showing that myricetin increases the lifespan of FOXO(-) is consistent with a previous report23, but not 
with another study reporting that FOXO is required for the myricetin-induced longevity24. In our experimental 
conditions, we used ethanol mixed with detergent (Tween 80) as a solvent control as previously described23, 
whereas Buchter et al. used DMSO as a solvent24. In light of the demonstrated effect of DMSO on the lifespan of 
C. elegans45, different experimental conditions such as solvents used may have resulted in, or contributed to, the 
functional differences. Together, our C. elegans data suggest that myricetin increased organismal lifespan and 
healthspan in a SIRT1-dependent manner. Further research will examine whether myricetin feeding can delay 
aging in mammals, which may ultimately accelerate the application of myricetin for general health and longevity.
Materials and Methods
Cell Culture and Molecular Biology Studies. C2C12 mouse myoblasts were maintained in DMEM (4.5 g 
glucose/L) supplemented with 10% fetal bovine serum, 1% Anti-Anti and cells were maintained at lower than 
80% confluence. Differentiation to myotubes was induced over 5 days by replacing the medium of confluent cul-
tures with DMEM containing 2% horse serum. Before myricetin (Sigma) treatment, cells were washed with PBS 
and incubated with DMEM containing 0.5% FBS treated for 24 hr with myricetin (10 or 30 or 100 μM) or DMSO. 
Methods for molecular assays are provided in the Supplemental Experimental Procedures.
In Vivo Analysis. Seven-week-old male ICR mice from Koatech Co. Ltd (Gyeonggi-do, Korea). All animal 
experiments were approved by the Ethics Review Committee of the Pohang center for the evaluation of biomate-
rials, Republic of Korea. Mice were housed in specific pathogen-free conditions with a 12 hr light-dark cycle and 
had free access to water and food. Body weight and caloric intake were monitored throughout the experiments. 
The mice were housed together and food intake was calculated of animals in the cage. 50 mg/kg/day myricetin 
or PBS, as the vehicle control, was orally administered daily for 3 weeks. The mice were sacrificed at the follow-
ing ages: 3 months by cervical vertebral dislocation, and liver (corresponding to left lobe), kidney, interscapular 
BAT, and gastrocnemius muscle were collected. The protocols used to assess behavioral, and metabolic pheno-
types included the following: energy expenditure by indirect calorimetry (12 hr, food and water) and 4 °C cold 
test(6 hr); circadian activity by metabolic cage monitoring (24 hr); locomoter function by rotarod, grip strength 
test; and endurance test by variable speed belt treadmill and incremental speed protocol (range from 18 cm/s to 
41 cm/s on habituated 2 hr fasted mice). Details are in the Supplemental Experimental Procedures.
Metabolic phenotypes. Metabolic analysis: To measure the food intake, physical activity, and metabolic 
rate, the mice were housed individually in a TSE indirect calorimetry system (Lab Master, TSE systems) for 24 hr 
with 12 h light/dark cycles at 22 ± 2 °C.
Thermogenesis test: The adaptive thermogenic response was measured in a cold tolerance test, during which 
the animals were individually housed at 4 °C for 6 hours.
Electron Microscopy. Liver (corresponding to left lobe), interscapular BAT, and gastrocnemius muscle were 
removed from mice and immediately put in 4% paraformaldehyde containing sodium cacodylate buffer (50 mM 
sodium cacodylate, pH 7.2) and kept at 4 °C. The tissues were then washed three times with sodium cacodylate 
buffer followed by postfixation with 1% osmium tetroxide in 50 nM sodium cacodylate buffer for 2 h at 4 °C. The 
samples were treated with 0.5% uranyl acetate at 4 °C for 30 min, followed by dehydration with a graded series of 
ethanol. Dehydrated samples were infiltrated with a graded series of propylene oxide and resin mix before to be 
embedded in 100% Spurr’s resin which was polymerized at 70 °C for 24 hr. Ultrathin sections were cut at 70 nm 
with an ultramicrotome (MT-X, RMC, Tucson, AZ, USA) and contrasted with 2% uranyl acetate and Reynolds’ 
lead citrate. Samples were examined with JEM-1011 electron microscope (JEOL, Tokyo, Japan). Our mitochon-
drial area measurements were largely similar to those described previously with minor modifications12. Briefly, 
for analyzing individual mitochondrial area, electron micrographs were digitized and the area of each clearly dis-
tinguishable mitochondria was analyzed using ImageJ. For each animal, regions containing numerous mitochon-
dria were analyzed in BAT, muscle or liver, for which at least 5 micrographs were captured, from different area of 
one grid. Mitochondria with length:width ratio>1.5 were considered as elongated mitochondria. Mitochondria 
containing these morphologies were counted and expressed as a percent of the total mitochondria. Mitochondrial 
areas and morphology of at least 90 mitochondrial profiles from each group were measured.
www.nature.com/scientificreports/
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Histology. In preparation for hematoxylin and eosin (HE) staining, the tissues were fixed in 10% formalin 
and embedded in paraffin. Sections of 3-μm thickness were affixed to slides, deparaffinized, dehydrated, and 
then stained with HE. Stained liver and kidney sections were observed under light microscopy (BX 50, Olympus, 
JAPAN). Each sample was observed at 400X magnification. The liver and kidney tissues from one mouse from the 
control, and 50 mg/kg myricetin treated groups were analyzed.
Serum analysis. Serum was collected by cardiac puncture, stored for 20 minutes at room temperature for 
coagulation and then separated by centrifugation at 2,000 × g for 40 minutes. The serum was stored at −70 °C 
until analysis. The levels of total protein, albumin, creatinine, triglycerides, total cholesterol, high‐density lipo-
protein (HDL)‐cholesterol, low‐density lipoprotein (LDL)‐cholesterol, uric acid, glucose, lactate dehydrogenase, 
alanine transaminase (ALT), aspartate transaminase (AST) and creatinine kinase in serum were measured by 
using an auto chemistry Equalizer (BS-390, Mindray Bio-medical Electronics Co., Ltd., China).
C. elegans study. Methods for C. elegans study are provided in the Supplemental Experimental Procedures.
Statistical analysis. Statistical analyses were performed with Prism software (GraphPad Prism 5, USA). We 
used student’s t test (two-tailed) for mice behavior, metabolic phenotypes, ex-vivo analysis, siRNA experiment 
and C. elegans study. For the multi dose of myricetin in vitro data, we applied one-way ANOVA followed by 
Tukey’s post hoc test. A P value < 0.05 was considered statistically significant.
Ethics Statement. Approval of the study protocol was obtained from the Advanced bio convergence center 
and Technology Institutional Animal Care and Use Committee (approval number: POCEB-011). All animal 
experiments were carried out according to the provisions of the Animal Welfare Act, PHS Animal Welfare Policy, 
and the principles of the NIH Guide for the Care and Use of Laboratory Animals. All mouse lines were main-
tained at the Advanced Bio Convergence Center animal facility under institutional guidelines.
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